4.66
price up icon0.22%   0.010
after-market After Hours: 4.66
loading
Inmed Pharmaceuticals Inc stock is traded at $4.66, with a volume of 32,750. It is up +0.22% in the last 24 hours and down -26.96% over the past month. InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
See More
Previous Close:
$4.65
Open:
$4.67
24h Volume:
32,750
Relative Volume:
0.63
Market Cap:
$3.35M
Revenue:
$5.49M
Net Income/Loss:
$-6.35M
P/E Ratio:
-0.8809
EPS:
-5.29
Net Cash Flow:
$-6.51M
1W Performance:
+8.86%
1M Performance:
-26.96%
6M Performance:
-33.98%
1Y Performance:
-38.68%
1-Day Range:
Value
$4.59
$4.97
1-Week Range:
Value
$3.65
$4.99
52-Week Range:
Value
$2.414
$15.70

Inmed Pharmaceuticals Inc Stock (INM) Company Profile

Name
Name
Inmed Pharmaceuticals Inc
Name
Phone
(604) 669-7207
Name
Address
1445-885 WEST GEORGIA ST., VANCOUVER
Name
Employee
13
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
INM's Discussions on Twitter

Compare INM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
INM 4.66 3.35M 5.49M -6.35M -6.51M -5.29
VRTX 450.97 116.14B 10.63B -479.80M -1.35B 13.33
REGN 738.00 81.10B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.23B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.12B 3.30B -501.07M 1.03B 11.54

Inmed Pharmaceuticals Inc Stock (INM) Latest News

pulisher
Nov 21, 2024

InMed Pharmaceuticals (FRA:MWG) EBITDA : €-6.11 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (FRA:MWG) Book Value per Share : €11.34 (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Accounts Receivable : €0.26 Mil (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Pre-Tax Income : €-6.25 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Days Inventory : 147.82 (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) GF Score : 43/100 (As of Nov. 21, 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Earnings per Share (Diluted) : €-59.16 (TTM As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Median PS Value : €0.00 (As of Nov. 21, 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Asset Turnover : 0.11 (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Net Income From Continuing Operations : €-6.25 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Cost of Goods Sold : €3.11 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Intrinsic Value: DCF (Earni - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Free Cash Flow : €-6.08 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) COGS-to-Revenue : 0.61 (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Cash Flow from Operations : €-6.08 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Earnings Yield (Joel Greenb - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Net-Net Working Capital : €5.86 (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Quick Ratio : 4.22 (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Debt-to-Revenue : 0.21 (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Price-to-Owner-Earnings : (As of Nov. 21, 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Cash-to-Debt : 5.28 (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted PB Rati - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Cash Flow for Dividends : €0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted FCF per Share : €-485.97 (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Price-to-Free-Cash-Flow : N/A (As of Nov. 21, 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted Book pe - GuruFocus.com

Nov 21, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Forward Dividend Yield % : 0.00% (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted PS Rati - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Inventories, Finished Goods : €0.84 Mil (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) 3-Year Book Growth Rate : -64.40% (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Other Current Liabilities : €0.21 Mil (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) EPS (Basic) : €-59.16 (TTM As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Other Long-Term Liabilities : €0.00 Mil (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Purchase Of Business : €0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Other Long Term Assets : €0.09 Mil (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Cash Ratio : 3.89 (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Cash Flow from Investing : €-0.01 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) EBIT : €-6.66 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (FRA:MWG) Peter Lynch Fair Value : €-1,493.15 (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Cash From Other Investing A - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Long-Term Capital Lease Obl - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Total Stockholders Equity : €7.56 Mil (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) EV-to-EBITDA : 0.22 (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted Revenue per Share : €68.91 (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Purchase Of Investment : €-0.04 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Change In Receivables : €-0.11 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) 3-Year EPS without NRI Grow - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

InMed Pharmaceuticals (STU:MWG) Issuance of Debt : €0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Inmed Pharmaceuticals Inc Stock (INM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Inmed Pharmaceuticals Inc Stock (INM) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
HULL ANDREW
Director
Feb 21 '24
Buy
0.39
37,500
14,625
38,258
ADAMS ERIC A
President & CEO
Feb 20 '24
Buy
0.36
41,600
14,922
43,959
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
Cap:     |  Volume (24h):